167 related articles for article (PubMed ID: 17034776)
1. Suggested functions for prolyl oligopeptidase: a puzzling paradox.
Brandt I; Scharpé S; Lambeir AM
Clin Chim Acta; 2007 Feb; 377(1-2):50-61. PubMed ID: 17034776
[TBL] [Abstract][Full Text] [Related]
2. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
[TBL] [Abstract][Full Text] [Related]
3. [Molecular modeling studies of prolyl endopeptidase inhibitors].
Kánai K; Fehér M; Lopata A; Podányi B; Novák I; Susán E; Hermecz I; Arányi P
Acta Pharm Hung; 1999 Nov; 69(5):240-6. PubMed ID: 10652791
[TBL] [Abstract][Full Text] [Related]
4. Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design.
Goossens F; Vanhoof G; De Meester I; Augustyns K; Borloo M; Tourwe D; Haemers A; Scharpé S
Eur J Biochem; 1997 Nov; 250(1):177-83. PubMed ID: 9432007
[TBL] [Abstract][Full Text] [Related]
5. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.
Jarho EM; Venäläinen JI; Huuskonen J; Christiaans JA; Garcia-Horsman JA; Forsberg MM; Järvinen T; Gynther J; Männistö PT; Wallén EA
J Med Chem; 2004 Nov; 47(23):5605-7. PubMed ID: 15509157
[TBL] [Abstract][Full Text] [Related]
6. The natural product berberine is a human prolyl oligopeptidase inhibitor.
Tarrago T; Kichik N; Seguí J; Giralt E
ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum.
Jalkanen AJ; Savolainen K; Forsberg MM
Neurosci Lett; 2011 Sep; 502(2):107-11. PubMed ID: 21820035
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease.
Stepniak D; Spaenij-Dekking L; Mitea C; Moester M; de Ru A; Baak-Pablo R; van Veelen P; Edens L; Koning F
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G621-9. PubMed ID: 16690904
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
Racys DT; Rea D; Fülöp V; Wills M
Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
[TBL] [Abstract][Full Text] [Related]
10. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase.
Gorrão SS; Hemerly JP; Lima AR; Melo RL; Szeltner Z; Polgár L; Juliano MA; Juliano L
Peptides; 2007 Nov; 28(11):2146-54. PubMed ID: 17904692
[TBL] [Abstract][Full Text] [Related]
12. Oligopeptidase B: a processing peptidase involved in pathogenesis.
Coetzer TH; Goldring JP; Huson LE
Biochimie; 2008 Feb; 90(2):336-44. PubMed ID: 18029266
[TBL] [Abstract][Full Text] [Related]
13. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
[TBL] [Abstract][Full Text] [Related]
14. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase.
Barelli H; Petit A; Hirsch E; Wilk S; De Nanteuil G; Morain P; Checler F
Biochem Biophys Res Commun; 1999 Apr; 257(3):657-61. PubMed ID: 10208839
[TBL] [Abstract][Full Text] [Related]
15. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
[TBL] [Abstract][Full Text] [Related]
16. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity.
Di Daniel E; Glover CP; Grot E; Chan MK; Sanderson TH; White JH; Ellis CL; Gallagher KT; Uney J; Thomas J; Maycox PR; Mudge AW
Mol Cell Neurosci; 2009 Jul; 41(3):373-82. PubMed ID: 19332125
[TBL] [Abstract][Full Text] [Related]
17. Sulfated chitooligosaccharides as prolyl endopeptidase inhibitor.
Je JY; Kim EK; Ahn CB; Moon SH; Jeon BT; Kim B; Park TK; Park PJ
Int J Biol Macromol; 2007 Dec; 41(5):529-33. PubMed ID: 17714777
[TBL] [Abstract][Full Text] [Related]
18. On the role of prolyl oligopeptidase in health and disease.
García-Horsman JA; Männistö PT; Venäläinen JI
Neuropeptides; 2007 Feb; 41(1):1-24. PubMed ID: 17196652
[TBL] [Abstract][Full Text] [Related]
19. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
[TBL] [Abstract][Full Text] [Related]
20. Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease.
Garcia-Horsman JA; Venäläinen JI; Lohi O; Auriola IS; Korponay-Szabo IR; Kaukinen K; Mäki M; Männistö PT
Scand J Gastroenterol; 2007 May; 42(5):562-71. PubMed ID: 17454876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
